sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Receives "Outperform" Rating in New Analyst Report
On July 8, 2026, NanoViricides, Inc., a company focused on developing antiviral drugs, announced an "Outperform" rating from an independent analyst report. Prepared by Noble Capital Markets, Inc., the report assigns a target price of $6.00 for the company's stock, citing promising ongoing programs. It highlights the potential of their lead antiviral drug, NV-387, which targets various viral infections including RSV and Influenza.
The report maintains that estimates and projections are solely the analyst's opinions, independent of NanoViricides' guidance. NanoViricides has been working with Noble Capital to enhance investor relations.
In addition, a "Fireside Chat" interview featuring President Dr. Anil Diwan was released, elucidating the company's progress and the effectiveness of NV-387 against emerging viral variants. This is crucial amid a global resurgence of diseases like Measles and Monkeypox, for which NanoViricides seeks to provide viable treatments.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.